Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DexSil is a line of consumer health products and supplements centered around organic silicon, specifically monomethylsilanetriol (MMST). Developed by the Belgian company Eytelia and distributed in Switzerland by Hygis, DexSil is designed to support connective tissue health. Silicon is a vital trace element that plays a crucial role in the formation and cross-linking of collagen and elastin fibers, which are essential for the structural integrity and elasticity of joints, bones, skin, hair, and nails. The DexSil product range includes oral solutions (often marketed as dietary supplements) and topical gels (often classified as medical devices), which may be enriched with additional ingredients such as glucosamine, chondroitin, or bio-activated nettle (Urtica dioica) to enhance their therapeutic effects on joint mobility and pain relief.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DexSil.